Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

NCT07220616 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07220616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07220616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 16, 2026
Completion date
November 30, 2030
Enrollment
420 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma, hematological malignancies